Abstract
Aim:
To explore cytotoxic T lymphocyte (CTL) response induced by the lipopeptide vaccine against cervical cancer.
Methods:
The immunological effect inducing CD8+ T cell-mediated cytotoxicity was investigated in human leukocyte antigen (HLA)-A2 transgenic mice and peripheral blood mononuclear cells (PBMC) of healthy HLA-A2.1+blood donor. The activity of specific CTL was measured by using a standard 4 h 51Cr release assay. The content of major histocompatibility complex (MHC) I on T2 cells and the expression of immune molecules on dendritic cells (DC) were detected by flow cytometry, and the concentrations of interleukin (IL)-12 and interferon-γ were determined by ELISA.
Results:
The lipopeptide induced a strong epitope-specific CTL response both in vivo (transgenic mice) and in vitro (human PBMC). This CTL induction was critically dependent on the presence of the helper T lymphocyte epitope in transgenic mice, and the presence of a lipid tail bypassed the need for an adjuvant. The stability and persistence of the antigenic complex formed with the lipopeptide increased in comparison with the CTL parental peptide. The lipopeptide could induce the production of IL-12 in DC, but not the maturation of DC directly.
Conclusion:
The combination of CTL and the T helper epitope and lipid molecule can remarkably improve the immunogenicity of the CTL peptide, the mechanism of which is associated with an increase in the stability and persistence of the antigenic complex formed with the lipopeptide and in the production of IL-12 in DC induced by the lipopeptide. The lipopeptide can be considered a more effective vaccine type for human being.
Similar content being viewed by others
Article PDF
References
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–9.
Ljubojevic S . The human papillomavirus vaccine. Acta Dermatovenerol 2006; 14: 208.
Govan VA . Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann N Y Acad Sci 2005; 1056: 328–43.
Hudson JB, Bedell MA, McCance DJ, Laiminis LA . Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990; 64: 519–26.
Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE . Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88: 110–4.
De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, De Cock KA, Ooms ME, et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998; 58: 724–31.
Melief CJ . Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143–75.
Greenberg PD . Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281–355.
Bona CA, Casares S, Brumeanu TD . Towards development of T-cell vaccine. Immunol Today 1998; 19: 126–33.
Bevan MJ . Helping the CD8+ T-cell response. Nat Rev immunol 2004; 4: 595–602.
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309–17.
BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ . Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002; 106: 113–21.
Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human popillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350–8.
BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997; 27: 1242–53.
Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type I lipopeptide vaccine. J Virol 2000; 74: 1694–703.
Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997; 159: 1383–92.
Shieh DC, Lin DT, Yang BS, Kuan HL, Kao KJ . High frequency of HLA-A0207 subtype in chinese population. Transfusion 1996; 36: 818–21.
Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A . Universally immunogenic T cell epitopes: promiscuous binding to human MHC class I and promiscuous recognition by T cells. Eur J Immunol 1989; 19: 2237–42.
Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4: 2103–9.
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A phase I trial of a human papillomavirus(HPV) pep-tide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6: 3406–16.
Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides. J Immunol 1995; 154: 5934–43.
Loing E, Andrieu M, Thiam K, Schorner D, Wiesmuller KH, Hosmalin A, et al. Extension of HLA-A0201-restricted minimal epitope by N-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J Immunol 2000; 164: 900–7.
Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T . Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 1999; 5: 2236–41.
Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, et al. Identification of HLA-A0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 2003; 9: 1850–7.
Wei WZ, Ratner S, Shibuya T, Yoo G, Jani A . Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cell. J Immunol Methods 2001; 258: 141–50.
Sallusto F, Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha. J Exp Med 1994; 179: 1109–18.
Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004; 64: 2610–8.
Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM . Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 1999; 170: 151–72.
Paul WE . Can the immune response control HIV infection? Cell 1995; 82: 177–82.
Gras-Masse H . Single-chain lipopeptide vaccines for the induction virus-specific cytotoxic T cell responses in randomly selected populations. Mol Immunol 2001; 38: 423–31.
Diamond DJ, York J, Sun JY, Wright CL, Forman SJ . Development of a candidate HLA-A0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90: 1751–67.
Mortara L, Gras-Masse H, Rommens C, Venet A, Guillet JG, Bourgault-Villada I . Type I CD4+ T cell help is required for induction of anti-peptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol 1999; 73: 4447–51.
Bessler WG, Mittenbuhler K, Esche U, Huber M . Lipopeptide adjuvants in combination treatment. Int Immunopharmacol 2003; 3: 1217–24.
Andrieu M, Loing E, Desoutter JF, Connan F, Choppin J, Gras-Masse H, et al. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8+ T lymphocyte activation. Eur J Immunol 2000; 30: 3256–65.
Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, et al. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 2003; 77: 1564–70.
Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995; 154: 5071–9.
Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigen. Immunol Rev 2004; 199: 9–26.
Mao YX, Chen YJ, Ge Y, Ma HB, Yu JF, Wu HY, et al. Recom-binant human B7-H4 expressed in Escherichia coli inhibits T lymphocyte proliferation and IL-2 secretion in vitro. Acta Pharmacol Sin 2006; 27: 741–6.
Ridge JP, Di Rosa F, Matzinger P . A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xu, Dh., Zhou, Ch., Xia, Yp. et al. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin 28, 695–702 (2007). https://doi.org/10.1111/j.1745-7254.2007.00538.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00538.x
Keywords
This article is cited by
-
Cancer Immunotherapy and Nanomedicine
Pharmaceutical Research (2011)